2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease
Open Access
- 11 July 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3553-3555
Abstract
The American Society of Hematology (ASH), International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF; now National Bleeding Disorders Foundation), and World Federation of Hemophilia (WFH) 2021 guidelines on the diagnosis and management of von Willebrand disease (VWD) included 11 recommendations on the diagnosis of VWD and 12 recommendations on the management of VWD, the most common inherited bleeding disorder. We describe the results of a review of the 2021 guidelines by the clinical co-chairs of the guideline panels requested by ASH to inform decision-making about the need for and timing of a guideline revision. An updated MEDLINE and Embase search applied the same terms as the ASH ISTH NHF WFH 2021 guidelines limited to studies from 2020 to 30 July 2024 (diagnosis) or 24 July 2024 (management). For the diagnosis of VWD, 432 studies were identified and underwent title and abstract review, with 17 undergoing full text review, and for the management of VWD, 288 studies were identified and underwent title and abstract review, with 37 undergoing full text review, to determine whether the data would change the strength or directionality of the existing recommendation or merit development of a new recommendation. Based on this review, the clinical co-chairs noted that none of the reviewed studies would change the direction or strength of the existing guideline recommendations. There will be continued monitoring of the ASH ISTH NHF WFH 2021 guidelines on the diagnosis and management of VWD to evaluate whether there is sufficient new evidence to warrant additional revisions.Keywords
This publication has 13 references indexed in Scilit:
- A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiativeHaemophilia, 2024
- Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trialThe Lancet Haematology, 2023
- Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study resultsBlood, 2022
- Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysisBlood Advances, 2022
- Outcomes of long‐term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature reviewHaemophilia, 2022
- Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literatureBlood Advances, 2022
- von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysisBlood Advances, 2021
- Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracyBlood Advances, 2021
- ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand diseaseBlood Advances, 2021
- ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand diseaseBlood Advances, 2021